S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:OPTN

OptiNose - OPTN Stock Forecast, Price & News

$1.71
-0.01 (-0.58%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.68
$1.75
50-Day Range
$1.68
$1.92
52-Week Range
$1.60
$4.30
Volume
95,932 shs
Average Volume
145,936 shs
Market Capitalization
$142.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67

OptiNose MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
172.9% Upside
$4.67 Price Target
Short Interest
Bearish
3.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.10
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$93,924 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.86) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

450th out of 1,026 stocks

Pharmaceutical Preparations Industry

215th out of 504 stocks

OPTN stock logo

About OptiNose (NASDAQ:OPTN) Stock

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Receive OPTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

OPTN Stock News Headlines

Optinose Announces CEO Transition and Business Update
Don’t Let The Markets Break Your Heart
Every rose has its thorn, just like every market has its surprise. If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right, or anticipate massive trend reversals with A.I. pixel
Optinose Appoints Paul Spence as Chief Commercial Officer
Bucks County health care company expects to raise $50M
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates
See More Headlines
Receive OPTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

OPTN Company Calendar

Last Earnings
11/10/2022
Today
2/08/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPTN
Fax
N/A
Employees
189
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.67
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+172.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-82,300,000.00
Pretax Margin
-96.64%

Debt

Sales & Book Value

Annual Sales
$74.65 million
Book Value
($0.26) per share

Miscellaneous

Free Float
79,511,000
Market Cap
$142.82 million
Optionable
Not Optionable
Beta
-0.25

Key Executives

  • Peter Kaighn Miller
    Chief Executive Officer & Director
  • Ramy A. MahmoudRamy A. Mahmoud
    President & Chief Operating Officer
  • John C. Messina
    SVP-Clinical Development & Medical Affairs
  • Michael C. Berkey
    Vice President-Technical Operations
  • Harry Sacks
    VP-Medical Affairs & Medical Officer













OPTN Stock - Frequently Asked Questions

Should I buy or sell OptiNose stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPTN shares.
View OPTN analyst ratings
or view top-rated stocks.

What is OptiNose's stock price forecast for 2023?

2 Wall Street analysts have issued twelve-month target prices for OptiNose's stock. Their OPTN share price forecasts range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.67 in the next year. This suggests a possible upside of 172.9% from the stock's current price.
View analysts price targets for OPTN
or view top-rated stocks among Wall Street analysts.

How have OPTN shares performed in 2023?

OptiNose's stock was trading at $1.85 at the beginning of 2023. Since then, OPTN stock has decreased by 7.6% and is now trading at $1.71.
View the best growth stocks for 2023 here
.

When is OptiNose's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our OPTN earnings forecast
.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) issued its quarterly earnings results on Thursday, November, 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The company had revenue of $20.08 million for the quarter, compared to analysts' expectations of $24.20 million.

What guidance has OptiNose issued on next quarter's earnings?

OptiNose issued an update on its FY 2022 earnings guidance on Tuesday, January, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.00 million-$78.00 million, compared to the consensus revenue estimate of $76.07 million.

What other stocks do shareholders of OptiNose own?
When did OptiNose IPO?

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Who are OptiNose's major shareholders?

OptiNose's stock is owned by many different institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (0.97%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Joseph C Scodari, Keith A Goldan, Keith A Goldan, Michael F Marino III, Michael F Marino III, Michele Janis, Peter K Miller, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli.
View institutional ownership trends
.

How do I buy shares of OptiNose?

Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $1.71.

How much money does OptiNose make?

OptiNose (NASDAQ:OPTN) has a market capitalization of $142.82 million and generates $74.65 million in revenue each year. The company earns $-82,300,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does OptiNose have?

The company employs 189 workers across the globe.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The official website for the company is www.optinose.com. The company can be reached via phone at (267) 364-3500 or via email at investors@optinose.com.

This page (NASDAQ:OPTN) was last updated on 2/9/2023 by MarketBeat.com Staff